DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model
Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, 1 Place Lucie et Raymond Aubrac, CEDEX 1, 63003 Clermont-Ferrand, France
Equipe d’Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, CEDEX 1, 63003 Clermont-Ferrand, France
Helixio, 63360 Saint-Beauzire, France
Author to whom correspondence should be addressed.
Academic Editor: Masahiro Kizaki
Received: 8 June 2021 / Revised: 9 July 2021 / Accepted: 13 July 2021 / Published: 17 July 2021
In Chronic Myeloid Leukemia (CML), intra-clonal heterogeneity is a major factor in the response to tyrosine kinase inhibitors and in leukemia stem cell persistence. This intra-clonal heterogeneity could be partially explained by epigenetic abnormalities. This review focuses on DNA methylation abnormalities in CML and its potential implications for the development of new biomarkers of the treatment response and new therapy opportunities. DNA methylation abnormalities are considered an important event in the CML progression phase. Moreover, in recent years, DNA methylation abnormalities have also been characterized at CML diagnosis (in the chronic phase), with specific alterations in the immature cells of the tumor clone. Lastly, the review discusses the importance of these finding for understanding the disease emergence, for developing new therapeutic strategies, and for a personalized management of CML.